{"id":"W4303470808","doi":"10.1159/000527403","title":"Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVRAZ (Canada)","funders":"European Commission; European Federation of Pharmaceutical Industries and Associations; University of Pittsburgh","keywords":"Regorafenib; Cabozantinib; Discontinuation; Medicine; Hepatocellular carcinoma; Sorafenib; Hazard ratio; Propensity score matching; Adverse effect; Internal medicine; Oncology; Surgery; Confidence interval; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001649486,0.0003626828,0.0009258218,0.0001732078,0.0003171675,0.00001551073,0.0001192627,0.0001005448,0.0009387053],"category_scores_gemma":[0.00001836228,0.0003346608,0.0002120334,0.000301007,0.00008253572,0.0001080107,0.00008116035,0.0001924043,0.000003282445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000387883,"about_ca_system_score_gemma":0.0002974969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00127139,"about_ca_topic_score_gemma":0.000363354,"domain_scores_codex":[0.9980012,0.0001456033,0.000493449,0.0006204066,0.0003294748,0.0004098244],"domain_scores_gemma":[0.9987333,0.0001982686,0.000270412,0.0004330508,0.0001143289,0.0002506519],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04211109,0.002511835,0.8599302,0.0004739705,0.001175917,0.0002966733,0.01156539,0.0001322382,0.01457082,0.0001934287,0.0002604853,0.066778],"study_design_scores_gemma":[0.2007279,0.06328855,0.2291334,0.0003549017,0.007851165,0.0001672224,0.007638796,0.06017115,0.3068607,0.00009703803,0.1214314,0.002277803],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839706,0.01193195,0.00003283628,0.0001883681,0.0003509762,0.002614448,0.0005194049,0.00008193473,0.0003094541],"genre_scores_gemma":[0.9959449,0.0003327676,0.0008442063,0.00006666062,0.0001477109,0.000903168,0.0007621344,0.00006881211,0.0009296269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6307968,"threshold_uncertainty_score":0.9999745,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1111477898344688,"score_gpt":0.3278793606080632,"score_spread":0.2167315707735943,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}